Parexel

Parexel is one of the world's largest contract research organisations, trusted by biopharmaceutical and medical device companies across more than 80 countries to design and execute the clinical programmes that bring new medicines to patients. Founded in 1982 and headquartered in Durham, North Carolina, the company has built decades of expertise spanning every stage of clinical development, from early-phase studies through to regulatory submission and post-marketing commitments.

Clinical Development & Regulatory Affairs

Parexel's core strength lies in its ability to manage complex, global clinical trials on behalf of sponsors who need both scientific rigour and operational scale. The company's therapeutic coverage is broad, with recognised depth in oncology, rare diseases, neuroscience, immunology, and infectious disease. Its regulatory affairs teams advise clients on approval strategy across major health authorities, including the FDA, EMA, and PMDA, drawing on longstanding relationships with agencies built over four decades of submissions.

Parexel Biotech & Technology Platforms

Parexel Biotech is a dedicated unit that serves emerging and mid-size biopharmaceutical companies, offering the same global infrastructure as the enterprise offering but with a service model calibrated to the pace and resource constraints of growing sponsors. Alongside this, the company has invested in its proprietary Parexel Informatics platform, which underpins trial data management, patient recruitment, and site performance monitoring. Rave, its electronic data capture product, is widely used across the clinical research industry.

The company operates a network of early-phase clinical pharmacology units and has particular capability in patient recruitment through its decentralised and hybrid trial models, reflecting broader industry shifts toward site-independent participation. Parexel was taken private by EQT and Goldman Sachs in 2021 after many years as a publicly listed company on NASDAQ, giving it greater flexibility to invest in long-term capability without quarterly earnings pressure.

With tens of thousands of employees and a presence spanning North America, Europe, Asia-Pacific, and Latin America, Parexel remains a primary strategic partner for companies navigating the regulatory path from discovery to approval. Further information is available at parexel.com.